JP2019536818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536818A5 JP2019536818A5 JP2019548783A JP2019548783A JP2019536818A5 JP 2019536818 A5 JP2019536818 A5 JP 2019536818A5 JP 2019548783 A JP2019548783 A JP 2019548783A JP 2019548783 A JP2019548783 A JP 2019548783A JP 2019536818 A5 JP2019536818 A5 JP 2019536818A5
- Authority
- JP
- Japan
- Prior art keywords
- myopathy
- muscle
- disease
- loss
- atrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023083666A JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1620119.6 | 2016-11-29 | ||
| GBGB1620119.6A GB201620119D0 (en) | 2016-11-29 | 2016-11-29 | Compounds |
| PCT/IB2017/057436 WO2018100483A1 (en) | 2016-11-29 | 2017-11-28 | Muscle performance improvement compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083666A Division JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536818A JP2019536818A (ja) | 2019-12-19 |
| JP2019536818A5 true JP2019536818A5 (https=) | 2021-01-14 |
| JP7683901B2 JP7683901B2 (ja) | 2025-05-27 |
Family
ID=58073474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548783A Active JP7683901B2 (ja) | 2016-11-29 | 2017-11-28 | 筋肉性能改善化合物 |
| JP2023083666A Pending JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083666A Pending JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11407799B2 (https=) |
| EP (1) | EP3548509A1 (https=) |
| JP (2) | JP7683901B2 (https=) |
| KR (1) | KR102622245B1 (https=) |
| CN (1) | CN110036024B (https=) |
| AU (1) | AU2017367277B2 (https=) |
| CA (1) | CA3045245A1 (https=) |
| GB (1) | GB201620119D0 (https=) |
| NZ (1) | NZ754625A (https=) |
| WO (1) | WO2018100483A1 (https=) |
| ZA (1) | ZA201903261B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110430890B (zh) | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| JP2023512423A (ja) * | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| CN116171147A (zh) * | 2020-07-24 | 2023-05-26 | 新加坡科技研究局 | 伤口愈合组合物及其用途 |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| US20250064952A1 (en) * | 2021-03-10 | 2025-02-27 | Acceleron Pharma Inc. | Actrii-alk4 antagonists and methods of treating heart failure |
| KR20240029031A (ko) | 2021-06-21 | 2024-03-05 | 쥬베나 테라퓨틱스, 인크. | 재생 폴리펩티드 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69434934D1 (de) * | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| US20100004171A1 (en) | 2006-08-08 | 2010-01-07 | Bazan Nicolas G | Therapeutic Methods for Neuropathic Pain |
| CA2661836A1 (en) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| ES2756725T3 (es) | 2007-02-09 | 2020-04-27 | Acceleron Pharma Inc | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| EP2295068A1 (en) * | 2009-09-04 | 2011-03-16 | Neurotune AG | Modified agrin-fragment capable of restoring muscle strength for use as a medicament |
| JP6267425B2 (ja) * | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
-
2016
- 2016-11-29 GB GBGB1620119.6A patent/GB201620119D0/en not_active Ceased
-
2017
- 2017-11-28 US US16/464,969 patent/US11407799B2/en active Active
- 2017-11-28 CA CA3045245A patent/CA3045245A1/en active Pending
- 2017-11-28 NZ NZ754625A patent/NZ754625A/en unknown
- 2017-11-28 WO PCT/IB2017/057436 patent/WO2018100483A1/en not_active Ceased
- 2017-11-28 JP JP2019548783A patent/JP7683901B2/ja active Active
- 2017-11-28 CN CN201780073720.2A patent/CN110036024B/zh active Active
- 2017-11-28 EP EP17808609.6A patent/EP3548509A1/en active Pending
- 2017-11-28 KR KR1020197018624A patent/KR102622245B1/ko active Active
- 2017-11-28 AU AU2017367277A patent/AU2017367277B2/en active Active
-
2019
- 2019-05-23 ZA ZA2019/03261A patent/ZA201903261B/en unknown
-
2023
- 2023-05-22 JP JP2023083666A patent/JP2023116479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536818A5 (https=) | ||
| JP2019535675A5 (https=) | ||
| Braun et al. | Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells | |
| Flesch et al. | Nonacidic farnesoid X receptor modulators | |
| JP2012070739A5 (https=) | ||
| TWI826358B (zh) | 用於治療肌肉萎縮和骨疾病的新型雜合ａｃｔｒｉｉｂ配體陷阱蛋白及其用途與生產方法 | |
| JP2014158480A5 (https=) | ||
| JP2019031494A (ja) | ペプチド模倣大環状分子 | |
| Zhang et al. | Apoptosis associated with Wnt/β-catenin pathway leads to steroid-induced avascular necrosis of femoral head | |
| JP2019141085A (ja) | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 | |
| Poggiogalle et al. | Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects | |
| Oh | The insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities | |
| BR122020006907B1 (pt) | Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| Romeo et al. | Humanin specifically interacts with amyloid-β oligomers and counteracts their in vivo toxicity | |
| RU2017138537A (ru) | Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией | |
| JP2006517581A5 (https=) | ||
| JP2017533889A (ja) | ペプチド模倣大環状分子およびその使用 | |
| TW201930286A (zh) | 側氧哌嗪衍生物 | |
| TW201000467A (en) | Novel 1,2,4-triazole derivatives and process of manufacturing thereof | |
| JP2022542016A (ja) | ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法 | |
| Park et al. | Serotonergic regulation of hepatic energy metabolism | |
| Shi et al. | Genetic syndromes with diabetes: a systematic review | |
| JP2017538407A5 (https=) | ||
| Li et al. | Basic biology and roles of CEBPD in cardiovascular disease | |
| Gronowski et al. | Acute nuclear actions of growth hormone (GH): cycloheximide inhibits inducible activator protein-1 activity, but does not block GH-regulated signal transducer and activator of transcription activation or gene expression |